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Introduction: Sputum eosinophilia occurs in approximately one-third of stable chronic 
obstructive pulmonary disease (COPD) patients and can predict exacerbation risk and response 
to corticosteroid treatments. Sputum induction, however, requires expertise, may not always 
be successful, and does not provide point-of-care results. Easily applicable diagnostic markers 
that can predict sputum eosinophilia in stable COPD patients have the potential to progress 
COPD management. This study investigated the correlation and predictive relationship between 
peripheral blood and sputum eosinophils. It also examined the repeatability of blood eosinophil 
counts.
Methods: Stable COPD patients (n=141) were classified as eosinophilic or noneosinophilic 
based on their sputum cell counts ($3%), and a cross-sectional analysis was conducted com-
paring their demographics, clinical characteristics, and blood cell counts. Receiver operating 
characteristic curve analysis was used to assess the predictive ability of blood eosinophils for 
sputum eosinophilia. Intraclass correlation coefficient was used to examine the repeatability 
of blood eosinophil counts.
Results: Blood eosinophil counts were significantly higher in patients with sputum eosinophilia 
(n=45) compared to those without (0.3×109/L vs 0.15×109/L; P,0.0001). Blood eosinophils 
correlated with both the percentage (ρ=0.535; P,0.0001) and number of sputum eosinophils 
(ρ=0.473; P,0.0001). Absolute blood eosinophil count was predictive of sputum eosinophilia 
(area under the curve =0.76, 95% confidence interval [CI] =0.67–0.84; P,0.0001). At a thresh-
old of $0.3×109/L (specificity =76%, sensitivity =60%, and positive likelihood ratio =2.5), 
peripheral blood eosinophil counts enabled identification of the presence or absence of sputum 
eosinophilia in 71% of the cases. A threshold of $0.4×109/L had similar classifying ability but 
better specificity (91.7%) and higher positive likelihood ratio (3.7). In contrast, $0.2×109/L 
offered a better sensitivity (91.1%) for ruling out sputum eosinophilia. There was a good agree-
ment between two measurements of blood eosinophil count over a median of 28 days (intraclass 
correlation coefficient =0.8; 95% CI =0.66–0.88; P,0.0001).
Conclusion: Peripheral blood eosinophil counts can help identify the presence or absence of 
sputum eosinophilia in stable COPD patients with a reasonable degree of accuracy.
Keywords: sputum eosinophilia, diagnostic accuracy, chronic obstructive pulmonary disease, 
stability of eosinophil counts
Introduction
Airway eosinophilia, a hallmark feature of asthma, is now a recognized inflammatory 
pattern in chronic obstructive pulmonary disease (COPD).1–3 Eosinophilic COPD, 
defined as sputum eosinophils $3%, is reported during acute exacerbations in up to 
28% of cases,4 and interestingly, in periods of disease stability, it is seen in approxi-
mately 34%5 (or 38%6) of COPD patients. Airway eosinophilia is a reliable predictor 
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of responsiveness to inhaled and oral corticosteroid therapies 
in COPD.6–9
The detection and measurement of airway eosinophilia 
mostly require the assessment of induced sputum.2 Although 
sputum induction is considered a direct and reliable method 
of assessing airway inflammation, it has a number of 
limitations.10,11 In addition to being unsuitable for point-of-care 
testing, it requires expertise and may not be always successful 
(failure rate of up to 30%).10,11 Due to these reasons, the search 
for minimally invasive and easily applicable diagnostic tools 
that can predict sputum eosinophilia in COPD and asthma has 
intensified.4,10,12–15 The use of peripheral blood cell counts as 
a potential alternative is attracting profound interest owing 
to its ease of application in clinical practice. The ability of 
blood eosinophils to predict sputum eosinophilia in patients 
with asthma has been reported, with promising results.15–18 In 
COPD, however, very few studies have addressed this, par-
ticularly during clinical stability. A recent report in 20 COPD 
patients and 21 healthy controls has demonstrated the associa-
tion between bronchial and blood eosinophil counts.19 Studies 
have also shown the potential ability of blood eosinophils to 
serve as a marker of response to corticosteroid treatments 
in exacerbating20 and stable21,22 COPD patients. The clinical 
characteristics of nonexacerbating COPD patients with per-
sistently elevated levels of blood eosinophils ($2%) and their 
longitudinal changes during a follow-up period of 3 years have 
also been investigated.3 Nevertheless, studies examining the 
utility of blood eosinophils in detecting sputum eosinophilia 
in stable COPD are still lacking.
In this study, we hypothesized that peripheral blood 
eosinophils can serve as a promising surrogate marker for 
sputum eosinophilia in stable COPD. To test this hypothesis, 
a cross-sectional analytical study of 141 stable COPD patients 
was conducted with the aim of investigating the correlation 
and predictive relationship between peripheral blood and 
sputum eosinophils. In addition, the stability of peripheral 
blood eosinophil counts between two measurements over a 
median period of 28 days was examined.
Methods
study design
A cross-sectional analytical study was conducted involv-
ing 141 patients with stable COPD (Figure 1). The data for 
71 participants were obtained from our previously published 
studies.5,23,24 The remaining 70 participants were recruited 
from the respiratory ambulatory care clinics at John Hunter 
Hospital (Newcastle, Australia), the clinical research 
databases of the Priority Research Centre for Asthma and 
Respiratory Disease at the University of Newcastle and the 
Hunter Medical Research Institute (Newcastle, Australia), 
and through community advertisement. All participants 
provided written informed consent, and ethics approval was 
obtained from the Human Ethics Research Committees of the 
Hunter New England Local Health District (12/12/12/3.06) 
and the University of Newcastle (H-2013-0010).
study participants
Adults (n=141) with stable COPD and paired blood and spu-
tum cell counts, which were obtained from samples collected 
during the same visit, were included. COPD diagnosis was 
confirmed by incompletely reversible airflow limitation (post-
bronchodilator forced expiratory volume in 1 second [FEV
1
] 
,80% predicted and FEV
1
 to forced vital capacity [FVC] ratio 
of ,0.7). Stable COPD was defined as no increase in bron-
chodilator use, no use of oral corticosteroids or antibiotics, no 
unscheduled doctor’s visit, or no hospitalization due to COPD 
in the past 4 weeks. Participants were assessed for demo-
graphic features, lung function, airway and peripheral blood 
inflammatory cell counts, smoking history, body mass index, 
preceding year exacerbation history, medical history, dyspnea 
(modified Medical Research Council [mMRC]),25 comor-
bidities (Charlson Comorbidity Index),26 and health-related 
quality of life (St George Respiratory Questionnaire).27 The 
BODEx (body mass index, airflow obstruction, dyspnea, 
severe exacerbation) index was also calculated.28
spirometry
Airflow limitation was assessed using spirometry (Medgraph-
ics, CPFS/D™ USB Spirometer, BreezeSuite v7.1, MGC 
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Figure 1 Study flowchart.
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Diagnostics, Saint Paul, MN, USA) to measure pre- and 
postbronchodilator FEV
1
, FVC, and FEV
1
/FVC according to 
the standards of the American Thoracic Society.29 The third 
National Health and Nutrition Examination Survey reference 
equations were used to calculate percent predicted.30
sputum induction and analysis
Sputum was induced using nebulized 4.5% saline in par-
ticipants whose FEV
1
 was $1 L, using our previously 
described methods.31 In those with FEV
1
 ,1 L, 0.9% saline 
was used. Lower respiratory sputum portions were selected 
and dispersed using dithiothreitol, and total cell count 
viability was performed. Cytospins were prepared, stained 
(May-Grunwald–Giemsa), and a differential cell count was 
obtained from 400 nonsquamous cells. Sputum samples 
obtained from all participants had squamous cell contamina-
tion less than 80% and were deemed adequate for further anal-
ysis.32 We defined eosinophilic COPD as sputum eosinophil 
count of $3%.33
Blood collection and analysis
Peripheral venous blood was collected into Vacutainer® tubes 
(BD Worldwide, North Ryde, NSW, Australia). Full blood 
counts were performed using standardized methods on a 
Beckman Coulter LH series analyzer (Beckman Coulter Ltd, 
Brea, CA, USA), through Hunter Area Pathology Service 
(Newcastle, Australia). The stability of peripheral blood 
eosinophils between two measurements, approximately 
28 days apart, was evaluated in 46 participants who had 
repeated measurements of blood cell counts.
statistical analysis
Data were analyzed using Stata 13 (Stata Corporation, 
College Station, TX, USA). Results are reported as mean ± 
standard deviation (SD) for normally distributed data and 
as median and interquartile range for nonparametric data. 
Student’s t-test was used for comparisons of normally 
distributed data, and Wilcoxon rank sum test was used for 
skewed data. Comparison of categorical data was done using 
Fisher’s exact test. Spearman’s rank correlation coefficient 
was used to examine the association between absolute blood 
cell counts/ratios and sputum eosinophils. Receiver operating 
characteristic (ROC) curves were generated, and the area 
under the curve (AUC) was calculated to assess the predic-
tive relationship between blood and sputum eosinophils. 
Intraclass correlation coefficient and Bland–Altman plot 
were used to determine the agreement between two measure-
ments of blood eosinophil counts. All results were reported 
as significant when P,0.05.
Results
Clinical characteristics
Table 1 presents the demographics and clinical characteristics 
of the 141 participants. Participants had a mean (SD) age of 
69.8±7.7 years and mean postbronchodilator predicted FEV
1
 
of 57.5%±17.9%. There were 89 (63.1%) males. Most of 
the participants (116, 82.3%) were ex-smokers with median 
pack-years of 37.5 (13.8, 62.5). In terms of GOLD (Global 
Initiative for Chronic Obstructive Lung Disease) grades, 
11 (7.8%) patients were in GOLD I, 74 (52.5%) in GOLD II, 
45 (31.9%) in GOLD III, and 11 (7.8%) in GOLD IV. With 
regard to the GOLD quadrants, using mMRC for symptom 
assessment, approximately half (53.9%) of the participants 
were in Quadrant D and 24.8% in Quadrant B. Over half 
(52.5%) were “frequent exacerbators”, having had two or 
more exacerbations in the past 12 months. Most (128, 90.8%) 
of the participants were prescribed maintenance inhaled 
corticosteroids (ICS) or ICS and long-acting β
2
 agonist 
(LABA) combination therapy (ICS/LABA), and of these, 
102 (72.3% of the total population) participants were also 
taking long-acting muscarinic antagonists (LAMA).
Eosinophilic airway inflammation (sputum eosinophil 
count $3%) was present in 45 (31.9%) participants. Clini-
cal characteristics were similar between those with sputum 
eosinophilia and those without, except for higher BODEx 
score (P=0.003) and more frequent high level of breathless-
ness (mMRC $2) (P=0.01) in the latter.
Peripheral blood cell counts/ratios
Both the absolute number and percentage proportion of 
blood eosinophils were significantly higher in eosinophilic 
COPD compared with noneosinophilic COPD (0.30×109/L 
vs 0.15×109/L, P,0.0001 and 3.95% vs 2.07%, P,0.0001, 
respectively) (Table 2, Figure 2A). Noneosinophilic partici-
pants had significantly elevated blood neutrophil counts com-
pared with the eosinophilic group (5.3×109/L vs 4.6×109/L, 
P=0.02). There was no difference in blood lymphocytes 
(P=0.84) and total white blood cell counts (P=0.32) between 
the two groups. Participants with sputum eosinophilia had 
significantly higher blood eosinophil/neutrophil ratio (ENR) 
and eosinophil/lymphocyte ratio (ELR), whereas those 
without had significantly higher neutrophil/lymphocyte ratio 
(Table 2, Figure 2B–D).
Correlation between blood and sputum 
eosinophils
A significant correlation was found between blood eosinophil 
counts and the proportion (ρ=0.535; P,0.0001) (Figure 3A) 
and number of sputum eosinophils (ρ=0.473; P,0.0001) 
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(Figure 3B). Similarly, percentage sputum eosinophils 
correlated reasonably well with both blood ELR (ρ=0.488; 
P,0.0001) and blood ENR (ρ=0.592; P,0.0001). No 
significant association was observed between percentage 
sputum neutrophils and blood neutrophil/lymphocyte ratio 
(ρ=0.0287; P=0.7355).
receiver operating characteristic (rOC) 
curve analysis
Absolute blood eosinophil count was predictive of sputum 
eosinophilia with AUC of 0.76 (95% confidence interval 
[CI] =0.67–0.84; P,0.0001) (Figure 4). Percentage blood 
eosinophils, blood ELR, and blood ENR were also predictive of 
Table 1 Demographics and clinical characteristics of the study population
Variable All participants (n=141) Eosinophilica (n=45) Noneosinophilicb (n=96) P-value*
age (years) 69.8±7.7 68.5±8.0 70.3±7.6 0.20
sex (male) 89 (63) 30 (67) 59 (61) 0.58
Postbronchodilator FeV1 (% predicted) 57.5±17.9 58.3±18.8 57.1±17.6 0.72
Postbronchodilator FeV1 (l) 1.5 (1.12, 1.79) 1.56 (1.09, 1.79) 1.48 (1.12, 1.78) 0.48
Postbronchodilator FeV1/FVC ratio (%) 56.55 (43.31, 65.57) 55.26 (44.4, 62.65) 57.12 (42.56, 65.92) 0.46
reversibility (l) 0.04 (0.006, 0.10) 0.04 (0, 0.08) 0.05 (0.008, 0.11) 0.48
reversibility (%) 4.46 (0.63, 10.22) 3.9 (0.0, 7.5) 4.67 (0.9, 11.0) 0.48
CCI score 3.9±1.1 3.8±1.0 3.9±1.1 0.71
Frequent vs nonfrequent exacerbatorsc 74 vs 67 (52.5 vs 47.5) 23 vs 22 (51.1 vs 48.9) 51 vs 45 (53.1 vs 46.9) 0.86
gOlD grade 1.00
I 11 (7.8) 3 (6.7) 8 (8.3)
II 74 (52.4) 24 (53.3) 50 (52.1)
III 45 (31.9) 15 (33.3) 30 (31.3)
IV 11 (7.8) 3 (6.7) 8 (8.3)
gOlD quadrant 0.003
a 9 (6.4) 5 (11.1) 4 (4.2)
B 35 (24.8) 7 (15.6) 28 (29.2)
C 21 (14.9) 13 (28.9) 8 (8.3)
D 76 (53.9) 20 (44.4) 56 (58.3)
BMI (kg/m2) 30.2 (25.5, 34.7) 30.4 (24.5, 33.3) 30.2 (26.1, 35.9) 0.32
ex-smokers 116 (82.3) 36 (80) 80 (83.3) 0.64
Pack years 37.5 (13.8, 62.5) 35.3 (9.8, 61.3) 38.4 (13.9, 63.4) 0.51
sgrQ 49.7±16.9 45.7±18.0 51.6±16.1 0.052
BODex 2 (1, 5) 2 (1, 3) 3 (2, 5) 0.003
mMrC score $2 96 (68.1) 24 (53.3) 72 (75.0) 0.01
ICs or ICs/laBa combination use 128 (90.8) 41 (91.1) 87 (90.6) 0.60
ICs dosed (μg/d) 500 (250, 500) 500 (250, 500) 500 (250, 500) 0.74
laMa use 110 (78.0) 35 (77.8) 75 (78.1) 0.56
Prior history of asthma 69 (48.9) 23 (51.1) 46 (47.9) 0.86
Notes: aParticipants with sputum eosinophil count $3%; bparticipants with sputum eosinophil count ,3%; cFrequent exacerbators: $2 exacerbations in the previous 
year, and nonfrequent exacerbators: ,2 exacerbations in the previous year; dICs dose calculated as beclomethasone equivalents where 1 μg of beclomethasone =1 μg 
budesonide =0.5 μg fluticasone; *P-value for the comparison of eosinophilic vs noneosinophilic COPD. Data expressed as mean ± sD, median (interquartile range) or as 
number (%).
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; CCI, Charlson comorbidity index; gOlD, global Initiative for Chronic Obstructive 
Lung Disease; BMI, body mass index; SGRQ, St George Respiratory Questionnaire; BODEx, body mass index, airflow obstruction, dyspnea, severe exacerbation; mMRC, 
modified Medical Research Council; ICS, inhaled corticosteroids; LABA, long-acting β2 agonist; laMa, long-acting muscarinic antagonists; sD, standard deviation.
Table 2 Blood cell count parameters and blood cell ratios
Blood cell counts/ratios All participants (n=141) Eosinophilica (n=45) Noneosinophilicb (n=96) P-value*
Blood eosinophils (×109/l) 0.20 (0.10, 0.30) 0.30 (0.20, 0.40) 0.15 (0.10, 0.20) ,0.0001
Blood eosinophils (%) 2.70 (1.56, 3.92) 3.95 (2.94, 5.08) 2.07 (1.35, 3.25) ,0.0001
Blood neutrophils (×109/l) 5.08±1.67 4.60±1.53 5.30±1.70 0.02
White blood cells (×109/l) 7.62±1.95 7.38±1.77 7.73±2.03 0.32
Blood lymphocytes (×109/l) 1.78±0.65 1.76±0.58 1.78±0.68 0.84
Blood nlr 2.84 (2.15, 3.85) 2.59 (2.07, 3.23) 3.00 (2.24, 4.00) 0.04
Blood elr 0.12 (0.07, 0.18) 0.15 (0.13, 0.24) 0.09 (0.06, 0.16) ,0.0001
Blood enr 0.04 (0.02, 0.06) 0.07 (0.04, 0.08) 0.03 (0.02, 0.05) ,0.0001
Notes: aParticipants with sputum eosinophil count $3%; bparticipants with sputum eosinophil count ,3%; *P-value for the comparison of eosinophilic vs noneosinophilic 
COPD. Data expressed as mean ± sD, median (interquartile range) or as number (%).
Abbreviations: nlr, neutrophil/lymphocyte ratio; elr, eosinophil/lymphocyte ratio; enr, eosinophil/neutrophil ratio; sD, standard deviation.
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sputum eosinophilia with AUCs of 0.80 (95% CI =0.73–0.86), 
0.74 (95% CI =0.65–0.83), and 0.81 (95% CI =0.73–0.89), 
respectively. The sensitivities and specificities of different 
cutoff points of absolute blood eosinophil counts were evalu-
ated together with their ability to correctly classify patients 
(Table 3). A summary of sensitivity and specificity for 
percentage blood eosinophils and blood ENR of different cut-
off points is provided in the Supplementary material (Tables S1 
and S2). The absolute blood eosinophil count threshold that 
balanced sensitivity and specificity on the ROC curve was 
found to be $0.3×109/L (300/μL), with a sensitivity of 60%, 
specificity of 76%, and a positive likelihood ratio of 2.5. 
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Figure 2 scatter dot plot comparing.
Notes: (A) Blood eosinophil count, (B) eosinophil/neutrophil ratio, (C) eosinophil/lymphocyte ratio, and (D) neutrophil/lymphocyte ratio between eosinophilic ($3% 
sputum eosinophils) and noneosinophilic COPD (,3% sputum eosinophils). graphs represent individual data points and a median as a bar (red).
Abbreviations: enr, eosinophil/neutrophil ratio; elr, eosinophil/lymphocyte ratio; nlr, neutrophil/lymphocyte ratio.
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At this cutoff point, blood eosinophil counts enabled the correct 
identification of the presence or absence of sputum eosinophilia 
in 71 cases out of 100. A higher cutoff point of $0.4×109/L 
(400/μL) gave a greater specificity (91.7%), a higher positive 
likelihood ratio (3.7), and an essentially similar classifying 
ability. In contrast, a higher degree of sensitivity (91.1%) 
was achieved at a peripheral blood eosinophil cutoff point of 
0.2×109/L (200/μL).
Based on the peripheral blood eosinophil threshold 
of $0.3×109/L, 76% of the noneosinophilic participants 
(73 out of 96) would be correctly characterized as not hav-
ing sputum eosinophilia (true negatives) while the remaining 
24% as false positives. On the other hand, 60% of the eosino-
philic participants (27 out of 45) would be accurately identi-
fied as having sputum eosinophilia (true positives) while the 
remaining 40% as false negatives. Two-by-two contingency 
tables for the blood eosinophil cutoff points of $0.2×109/L 
and $0.4×109/L are provided in the Supplementary material 
(Tables S3 and S4).
Clinical characteristics of participants classified 
by blood eosinophil counts
Blood eosinophilia (blood eosinophil count $0.4×109/L) 
was present in 22 (15.6%) participants (Table 4). Patients 
with blood eosinophilia had a higher postbronchodilator 
FEV
1
% predicted and a lower BODEx score compared to 
those without (,0.4×109/L). All other clinical parameters 
were similar between the two groups. There were no differ-
ences in blood eosinophil counts between males and females 
(0.2 [0.1, 0.3] ×109/L and 0.2 [0.1, 0.3] ×109/L; P=0.9087), 
ex-smokers and never smokers (0.2 [0.1, 0.3] ×109/L and 
0.2 [0.1, 0.3] ×109/L; P=0.8848), frequent and nonfrequent 
exacerbators (0.2 [0.1, 0.3] ×109/L and 0.2 [0.1, 0.3] ×109/L; 
P=0.96), or between patients taking ICS(/LABA) and those 
who did not (0.2 [0.1, 0.3] ×109/L and 0.1 [0.1, 0.2] ×109/L; 
P=0.221).
stability study
This study also assessed the stability of peripheral blood 
eosinophil counts in those participants who had repeated mea-
surements of blood cell counts obtained from blood samples 
collected at two visits spaced a median of 28 (22.5, 35.5) 
days apart (n=46). There was a good agreement between 
the two measurements, with an intraclass correlation coef-
ficient of 0.8 (95% CI =0.66–0.88; P,0.0001). The bias of 
measurement was negligible (0.002±0.13 [×109/L]), with 
equal scatter around the bias line, indicating no systematic 
measurement bias (Figure 5).
Discussion
This study, which assessed the ability of peripheral blood 
eosinophils for detecting sputum eosinophilia in stable COPD, 
had three main findings. First, peripheral blood eosinophil 
count was shown to distinguish patients with sputum eosino-
philia from those without, thereby indicating its potential use 
as a diagnostic biomarker for eosinophilic COPD. Second, 
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Figure 4 receiver operating characteristic (rOC) curve for absolute blood 
eosinophil count to predict sputum eosinophilia ($3%).
Note: Points on the ROC curve are presented as (specificity %, sensitivity %).
Table 3 Summary of sensitivity and specificity for different blood eosinophil cutoff points for detecting sputum eosinophilia
Blood eosinophil cutoff 
points (×109/L)
Sensitivity (%) Specificity (%) Correctly 
classified (%)
LR (+) LR (-)
$0.1 97.8 6.3 35.5 1.04 0.36
$0.2 91.1 50.0 63.1 1.82 0.18
$0.3 60.0 76.0 70.9 2.50 0.53
$0.4 31.1 91.7 72.3 3.73 0.75
$0.5 13.3 94.8 68.8 2.56 0.91
$0.6 8.9 99.0 70.2 8.53 0.92
$0.7 4.4 100.0 69.5 a 0.96
Note: aThe lr (+) at this cutoff point is incalculable (with 0 as a denominator).
Abbreviations: lr (+), positive likelihood ratio; lr (-), negative likelihood ratio.
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we have shown that blood eosinophil counts and their ratios 
(ELR and ENR) are elevated in eosinophilic COPD and 
correlate reasonably well with sputum eosinophilia. Third, 
blood eosinophil counts between two measurements over a 
median period of 28 days were found to be stable.
The diagnostic performance of peripheral blood eosino-
phils in identifying eosinophilic airway inflammation in mild, 
moderate, and severe asthma has been previously 
investigated.13–18,34 Studies examining the potential utility 
of blood eosinophils in COPD, particularly during stable 
conditions, are however few.3,19–21 One study in COPD has 
shown that peripheral percentage blood eosinophil count 
(.2%) can serve as a sensitive biomarker to determine spu-
tum eosinophilia (.3%) during exacerbations (AUC 0.85 
[95% CI =0.78–0.93], sensitivity =90%, specificity =60%).4 
This AUC result is similar to our present AUC result in 
stable COPD.
Table 4 Demographics and clinical characteristics of participants with and without blood eosinophilia
Variable Participants with blood 
eosinophilia ($0.4×109/L)
Participants without blood 
eosinophilia (,0.4×109/L)
P-value*
number 22 (15.6) 119 (84.4) na
age (years) 70.1±7.5 69.7±7.8 0.84
sex (male) 13 (59.1) 76 (63.9) 0.81
Postbronchodilator FeV1 (% predicted) 65.1±19.3 56.1±17.4 0.03
Postbronchodilator FeV1 (l) 1.56 (1.2, 1.88) 1.48 (1.12, 1.79) 0.31
Postbronchodilator FeV1/FVC ratio (%) 58.82±14.83 54.64±14.79 0.23
reversibility (l) 0.025 (0, 0.12) 0.045 (0.01, 0.1) 0.51
reversibility (%) 2.5 (0, 12.03) 4.55 (0.95, 9.66) 0.51
CCI score 4 (3, 5) 4 (3, 4) 0.14
Frequent vs nonfrequent exacerbatorsa 13 vs 9 (59.1, 40.9) 61 vs 58 (51.2, 48.8) 0.64
number of severe exacerbation 0 (0, 1) 0 (0, 1) 0.60
gOlD grade 0.23
I 4 (18.2) 7 (5.9)
II 12 (54.5) 62 (52.1)
III 5 (22.7) 40 (33.6)
IV 1 (4.5) 10 (8.4)
gOlD quadrant 0.16
a 0 (0) 9 (7.6)
B 3 (13.6) 32 (26.9)
C 6 (27.3) 15 (12.6)
D 13 (59.1) 63 (52.9)
BMI (kg/m2) 31.1 (26.7, 34.5) 30.2 (25.5, 34.9) 0.91
ex-smokers 19 (86.4) 97 (81.5) 0.77
Pack years 22.3 (9, 42) 38.8 (15, 65) 0.06
sgrQ 44.2 (32.8, 66.6) 50.2 (38, 61.1) 0.89
BODex 2 (1, 3) 3 (1, 5) 0.047
mMrC score $2 12 (54.5) 84 (59.6) 0.14
ICs or ICs/laBa combination use 22 (100) 106 (89.1) 0.22
ICs doseb (μg/d) 500 (400, 500) 500 (250, 500) 0.16
laMa use 16 (72.7) 94 (79) 0.52
Prior history of asthma 12 (55) 57 (48) 0.65
Notes: aFrequent exacerbators: $2 exacerbations in the previous year, and nonfrequent exacerbators: ,2 exacerbations in the previous year; bICs dose calculated as 
beclomethasone equivalents where 1 μg of beclomethasone =1 μg budesonide =0.5 μg fluticasone. Data expressed as mean ± standard deviation, median (interquartile range) 
or as number (%); *P-value for the comparison of participants with and without blood eosinophilia.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; CCI, Charlson Comorbidity Index; gOlD, global Initiative for Chronic Obstructive 
Lung Disease; BMI, body mass index; SGRQ, St George Respiratory Questionnaire; BODEx, body mass index, airflow obstruction, dyspnea, severe exacerbation; mMRC, 
modified Medical Research Council; ICS, inhaled corticosteroids; LABA, long-acting β2 agonist; laMa, long-acting muscarinic antagonists; na, not applicable.
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Figure 5 Bland–altman plot showing the difference between the absolute blood 
eosinophil counts of two measurements against the mean of the absolute blood 
eosinophil counts of the two measurements.
Notes: The blue line represents the mean of differences (bias line). horizontal 
dotted lines represent the 95% limits of agreement (mean difference ±1.96 sD).
Abbreviation: sD, standard deviation.
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As noted by Korevaar et al,14 optimal cutoff points for 
diagnostic biomarkers of airway eosinophilia selected by 
balancing sensitivity and specificity on a ROC curve may 
not be clinically applicable, given that their sensitivity and/or 
specificity is often suboptimal compared to that of reference 
standard tests, such as bronchoalveolar lavage and sputum 
induction. From the clinical point of view, the choice of a cut-
off point is also partly determined by the clinical question. In 
view of this, we have evaluated the sensitivity and specificity 
of blood eosinophil counts at different cutoff points (Table 3). 
According to our data, in patients with stable COPD, periph-
eral blood eosinophil counts can help correctly identify the 
presence or absence of sputum eosinophilia in 71 cases 
out of 100 at cutoff points of $0.3×109/L or $0.4×109/L. 
Nevertheless, the higher cutoff point had a higher positive 
predictive value (PPV) (number of true positives/[number of 
true positive + number of false positives]) and a much better 
specificity to rule in sputum eosinophilia. This implies that 
patients with blood eosinophil counts above the threshold of 
0.4×109/L would most likely have COPD with eosinophilic 
airway inflammation. Akin to the suggestion of Fowler et al,17 
such patients may not necessarily need to undergo induction 
of sputum for the assessment of airway eosinophilia. Patients 
with blood eosinophil count of ,0.4×109/L may however 
need further assessment because the proportion of false nega-
tives at the cutoff point of 0.4×109/L is high (~69%). As a 
matter of interest, a similar blood eosinophil cutoff point of 
$0.45×109/L has been reported to help correctly identify 
sputum eosinophilia in patients with severe asthma with a 
specificity of 97%, sensitivity of 49.3%, and PPV of 89.2.17 
Another recent study has also reported a blood eosinophil 
cutoff point of $0.41×109/L (specificity of 95%, sensitivity 
of 36%, and PPV of 79) for detecting sputum eosinophilia in a 
population of asthmatic patients of different phenotypes.15
For a clinician who wants to rule out sputum eosinophilia, 
on the other hand, a peripheral blood eosinophil cutoff point 
with a high sensitivity would be of interest. Based on our 
results, patients are unlikely to have sputum eosinophilia if 
their blood eosinophil count is below 0.2×109/L because the 
sensitivity at the cutoff point of 0.2×109/L is 91.1%.
It is interesting to note that in our study, there was dis-
cordance between sputum and blood eosinophils in approxi-
mately 40% of the patients with eosinophilic COPD at a 
peripheral blood eosinophil cutoff point of 0.3×109/L. This 
observation is similar to that of a recent study in patients 
with uncontrolled asthma where one-third of the participants 
exhibited discordance between blood and sputum eosino-
phils.35 In order to gain a better insight into our true-positive 
(27 patients) and false-negative (18 patients) cohorts, their 
demographic features, clinical characteristics, and sputum 
cell counts were compared. The results nevertheless revealed 
no significant difference between the two groups (Table S5). 
However, it should be highlighted that this analysis may have 
been underpowered due to small sample size.
Plausible causes for the discordance between sputum 
and blood eosinophils may include the imbalance between 
the production and subsequent clearance of eosinophils 
by airway macrophages36 and variations in the process of 
recruitment of eosinophils into the airways.35 The fact that 
only a proportion of the eosinophilic COPD patients had 
blood eosinophilia may suggest the involvement of more than 
one distinct biological mechanisms underlying eosinophilic 
airway inflammation within this COPD phenotype.37 As in 
the case of asthma, Th2 cytokines could be responsible for 
inflammation in eosinophilic COPD.37 Nevertheless, eosino-
philic airway inflammation in the absence of elevated levels 
of Th2 has also been reported in some COPD patients.38 One 
potential mechanism for the non-Th2 eosinophilic inflamma-
tion in COPD could be the epithelial-innate lymphoid cell 
type 2 (ILC2) pathway, which has been suggested to play 
a similar role in severe nonallergic asthma.39 Obviously, 
further investigation is warranted to understand the mecha-
nism underlying the different endotypes of the eosinophilic 
COPD phenotype.
Our data demonstrated that blood eosinophils and their 
ratios (ELR and ENR) were elevated in patients with sputum 
eosinophilia compared with those without. Absolute blood 
eosinophil counts correlated reasonably well with both the 
absolute sputum counts and percentage sputum eosinophils, 
which is in agreement with the findings of Wagener et al,18 
Zhang et al,16 and Fowler et al17 in asthma, but not with those 
of Hastie et al34 and Amorim et al.40 In accordance with a 
previous finding in asthma,16 in our study, both blood ENR 
and ELR also correlated with percentage sputum eosinophils 
and were predictive of eosinophilic COPD with AUCs of 
0.81 and 0.74, respectively. Recently, Khatry et al41 have 
suggested that ratios of blood cell types, such as ELR and 
ENR, may minimize variations associated with measurement, 
sample processing, and therapies and yield a more accurate 
diagnostic performance over actual blood cell counts. This 
certainly will be a topical issue for future studies in COPD.
According to Price et al,42 blood eosinophilia (defined 
as $0.5×109/L) occurs in 10% of stable COPD patients and 
is associated with higher rate of exacerbations, particularly in 
nonsmokers receiving maintenance therapy. Elevated levels of 
blood eosinophils in COPD patients have also been associated 
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with increased risk of mortality from exacerbations.43 Nev-
ertheless, our analysis indicated no significant difference in 
blood eosinophil counts between frequent and nonfrequent 
exacerbators. Similarly, there was no difference in the num-
ber of severe exacerbations in the past 12 months between 
patients with blood eosinophilia ($0.4×109/L) and those 
without (,0.4×109/L). It is worth noting here that up to 90% 
of our study population was using either ICS/LABA alone 
or in combination with LAMA, which are known to reduce 
the risk of exacerbation. All things considered, the aforemen-
tioned discrepancies may possibly be due to differences in 
the characteristics of study populations.
In our study, the stability of peripheral blood eosinophil 
counts between two measurements over a median period 
of 28 days was found to be acceptable. This implies that 
a single measurement of blood eosinophil count may provide 
indicative information about eosinophilic airway inflamma-
tion status in stable COPD. The stability of peripheral blood 
eosinophil counts in repeated measurements in COPD popu-
lation has been reported in other studies as well.20,21
Conclusion
In this study, we found a predictive relationship between 
blood and sputum eosinophils in stable COPD. Peripheral 
blood eosinophils were stable between two measurements, 
suggesting that a single blood eosinophil count may poten-
tially serve as a reliable marker for eosinophilic COPD. A 
potential limitation of this study may be the fact that we did 
not have bronchoalveolar lavage or endobronchial biopsy 
samples for the assessment of airway eosinophilia.
The clinical relevance of our work lies in the fact that 
a simple blood test may allow the clinician to positively 
diagnose eosinophilic COPD. In relation to this, the question 
of when to use ICS in COPD is of high clinical importance. 
Biomarkers that allow for the identification of patients who 
are most likely to respond to ICS, and consequently minimize 
harm arising from inappropriate treatment, have the potential 
to significantly progress COPD management. In this regard, 
it will be interesting and a worthwhile endeavor to examine 
ICS response at different blood eosinophil thresholds in 
future prospective studies.
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